Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity lowers target price on Arrow Exploration

(Sharecast News) - Analysts at Canaccord Genuity lowered their target price on Arrow Exploration from 32.0p to 28.0p on Thursday as it took a "more cautious approach" to the firm's production profile. Canaccord Genuity said FY24 was "a bumper year" for Arrow, with production rising 63% and revenue up 65%. It also noted that while this growth required increased investment, year-end cash still rose from $12.1m to $18.8m.

The Canadian bank also said the upturn "really gained pace" in H224, with a step up in production at its Carrizales Norte asset following horizontal well drilling success, leading to Q424 production of 4,700 barrels of oil equivalent per day - double that of Q324.

Still, Canaccord took the more cautious approach to the production profile and said it had not included any production from Arrow's exploration targets until discoveries were made.

"As a result, we exclude potential new target development drilling from our capex profile. For 2026 and beyond, we currently assume a much lower capex programme with associated production declines. Exploration success and/or further intense development drilling could significantly change that profile," said Canaccord, which has a 'buy' rating on the stock.

"Our lowered production profile in combination with higher anticipated realised oil price discounts results in a reduced risked NPV12.5 target price of 28p (from 32p)."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.